Giles Robinson, Neuro-Oncology Division Director at the St. Jude Children’s Research Hospital, shared a post on LinkedIn:
“Jessica came to us at St. Jude Children’s Research Hospital after being diagnosed with a diffuse midline glioma (DMG), an aggressive pediatric brain tumor driven by the H3 K27M mutation.
These tumors remain among the most challenging diseases we face in pediatric neuro-oncology. They are biologically complex, deeply embedded within critical brain structures, and extraordinarily difficult to treat.
She was a fierce motocross competitor, a young woman whose determination on the track carried into every step of her treatment journey. Even in the face of progression, experimental therapies, radiation, clinical trials, hydrocephalus, and vision loss, she continued to meet each day with resilience, humor, and unwavering faith.
As physicians and scientists, we often speak about ‘advancing the field.’ What that really means is learning from courageous patients and families who choose to participate in research despite uncertainty.
As we observe Brain Tumor Awareness Month and Clinical Trials Day, Jessica’s willingness to undergo biopsy and participate in clinical trials contributed to a growing body of knowledge that is helping us better understand DMG biology, PI3 kinase pathway activation, tumor microenvironment signaling, and potential therapeutic vulnerabilities.
The work is far from over, but progress is happening because of patients like Jessica.”
Other articles about Brain Tumor on OncoDaily.